Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
Business Summary
Number of employees: 3,637
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 3,738 | 100.0 % | 5,961 | 100.0 % | +59.47% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
89.2
%
| 3,303 | 88.4 % | 5,316 | 89.2 % | +60.92% |
North America
5.8
%
| 169 | 4.5 % | 348 | 5.8 % | +106.21% |
Asia Pacific (excluding China)
3.6
%
| 208 | 5.6 % | 214 | 3.6 % | +3.00% |
Europe
1.0
%
| 58 | 1.6 % | 62 | 1.0 % | +6.83% |
South America
0.4
%
| - | - | 21 | 0.4 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wei Dong Jiang
FOU | Founder | - | 09-11-30 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 21-11-29 |
Wei Huang
PSD | President | 56 | 20-09-30 |
Wen Jie Zhang
CHM | Chairman | 57 | 19-02-28 |
Simon Hsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Miao Jie Chen
CMP | Compliance Officer | 41 | - |
Ye Xing Yuan
BRD | Director/Board Member | 39 | 22-12-31 |
Jin Li
LAW | General Counsel | - | 21-09-12 |
Jing Li
PRN | Corporate Officer/Principal | - | - |
Ping Cao
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 13-01-14 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 18-12-23 |
Yi Fang Wu
BRD | Director/Board Member | 54 | 15-06-11 |
Rui Lin Song
BRD | Director/Board Member | 61 | 19-09-01 |
De Yong Wen
BRD | Director/Board Member | 52 | 22-07-27 |
Lik Yuen Chan
BRD | Director/Board Member | 55 | - |
Wen Jie Zhang
CHM | Chairman | 57 | 19-02-28 |
Rong Li Feng
CHM | Chairman | 49 | 20-04-20 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 21-11-29 |
Ye Xing Yuan
BRD | Director/Board Member | 39 | 22-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 380,066,312 | 0 | 0 | 15.03 % |
Stock B | 1 | 163,428,541 | 81,687,447 ( 49.98 %) | 0 |
Company contact information
Shanghai Henlius Biotech, Inc.
Innov Tower 1801 Hongmei Road, Xuhui District
200233, Shanghai
+
http://www.henlius.comSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+5.24% | 9.06B |
- Stock Market
- Equities
- 2696 Stock
- Company Shanghai Henlius Biotech, Inc.